Deng Jie, Wang Yi
Department of Medical Imaging, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Chronic Dis Transl Med. 2017 Mar 11;3(1):8-20. doi: 10.1016/j.cdtm.2017.02.002. eCollection 2017 Mar 25.
Radiological imaging plays an important role in oncological trials to provide imaging biomarkers for disease staging, stratifying patients, defining dose setting, and evaluating the safety and efficacy of new candidate drugs and innovative treatment. This paper reviews the techniques of most commonly used quantitative magnetic resonance imaging (qMRI) biomarkers (dynamic contrast enhanced, dynamic susceptibility contrast, and diffusion weighted imaging) and their applications in oncological trials. Challenges of incorporating qMRI biomarkers in oncological trials are discussed including understanding biological mechanisms revealed by MRI biomarkers, consideration of rigorous trial design and standardized implementation of qMRI protocols.
放射成像在肿瘤学试验中发挥着重要作用，可为疾病分期、患者分层、确定剂量设置以及评估新候选药物和创新治疗的安全性和有效性提供成像生物标志物。本文综述了最常用的定量磁共振成像（qMRI）生物标志物技术（动态对比增强、动态磁敏感对比和扩散加权成像）及其在肿瘤学试验中的应用。讨论了在肿瘤学试验中纳入qMRI生物标志物所面临的挑战，包括理解MRI生物标志物揭示的生物学机制、考虑严格的试验设计以及qMRI协议的标准化实施。
